Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Heron Therapeutics Inc. shares valued at $7,154 were sold by MANHARD KIMBERLY on May 03. At $4.76 per share, MANHARD KIMBERLY sold 1,504 shares. The insider’s holdings dropped to 10,872 shares worth approximately $47075.76 following the completion of this transaction.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now.
Also, Christian Waage sold 300 shares, netting a total of over 2,920 in proceeds. Following the sale of shares at $9.73 each, the insider now holds 3,200 shares.
Before that, Johnson Craig A had sold 250 shares from its account. In a trade valued at $2,432, the Director traded Heron Therapeutics Inc. shares for $9.73 each. Upon closing the transaction, the insider’s holdings decreased to 250 shares, worth approximately $12297.2.
As published in their initiating research note from Guggenheim on May 27, 2020, Heron Therapeutics Inc. [HRTX] has been a Buy and the price target has been revised to $24. This represents a 81.96% premium over Wednesday’s closing price. Analysts at Needham resumed the stock at ‘”a Buy”‘ outlook in a report released in mid February. As of January 16, 2019, Needham has reiterated its “Buy” rating for HRTX. Earlier on April 05, 2018, Evercore ISI initiated its rating. Their recommendation was “an Outperform” for HRTX stock.
Analyzing HRTX’s Price Performance
On Wednesday, Heron Therapeutics Inc. [NASDAQ: HRTX] plunged -7.28% to $4.33. The stock’s lowest price that day was $4.33, but it reached a high of $4.805 in the same session. During the last five days, there has been a drop of approximately -6.88%. Over the course of the year, Heron Therapeutics Inc. shares have dropped approximately -52.57%. Shares of the company reached a 52-week high of $10.40 on 01/04/22 and a 52-week low of $2.19 on 06/13/22. A 50-day SMA is recorded $4.00, while a 200-day SMA reached $5.51. Nevertheless, trading volume fell to 3.31 million shares from 3.23 million shares the previous day.
Support And Resistance Levels for Heron Therapeutics Inc. (HRTX)
According to the 24-hour chart, there is a support level at 4.17, which, if violated, would cause prices to drop to 4.01. In the upper region, resistance lies at 4.65. The next price resistance is at 4.96. RSI (Relative Strength Index) is 47.77 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.04, which suggests the price will decrease in the coming days. Percent R is at 61.60%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Heron Therapeutics Inc. subject to short interest?
Stocks of Heron Therapeutics Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 1.2 million shares to 40.18 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 38.98 million shares. A jump of 2.99% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 13.42 of the overall float, the days-to-cover ratio (short ratio) jumped to 13.42.
Which companies own the most shares of Heron Therapeutics Inc. (HRTX)?
According to SSgA Funds Management, Inc. filings, the company currently owns 16,328,796 shares, which is about 13.34% of the total HRTX shares outstanding. The investor’s shares have appreciated by 3,405,427 from its previous 13-F filing of 12923369.0 shares. Franklin Advisers, Inc. acquire a 0.05% interest valued at $48.03 million while UBS O’Connor LLC purchased a 298,000 stake. A total of 0 shares of Heron Therapeutics Inc. were bought by Baker Bros. Advisors LP during the quarter, and -1,979,037 were sold by The Vanguard Group, Inc. In its current portfolio, BlackRock Fund Advisors holds 6,770,072 shares valued at $27.69 million.
In terms of Heron Therapeutics Inc. share price expectations, FactSet research, analysts set an average price target of $13.42 in the next 12 months, up nearly 135.55% from the previous closing price of $4.67. Analysts anticipate Heron Therapeutics Inc. stock to reach $30.00 by 2022, with the lowest price target being $5.50. In spite of this, 6 analysts ranked Heron Therapeutics Inc. stock as a Buy at the end of 2022. On March 19, 2018, Mizuho assigned a price target of “a Buy” to the stock and reiterated coverage with a $35.